الصفحة الرئيسية>>Signaling Pathways>> Proteases>> Lipoxygenase>>COX/5-LO-IN-1

COX/5-LO-IN-1 (Synonyms: Atreleuton analog)

رقم الكتالوجGC31967

COX / 5-LO-IN-1 (تناظرية Atreleuton) هو مثبط لانزيم سيلوكسيجيناز و 5-ليبوكسجيناز (5-LO) ، ويستخدم في البحث عن حالات الأمراض الالتهابية والحساسية

Products are for research use only. Not for human use. We do not sell to patients.

COX/5-LO-IN-1 التركيب الكيميائي

Cas No.: 154355-75-6

الحجم السعر المخزون الكميّة
1mg
1049٫00
متوفر
5mg
2096٫00
متوفر
10mg
3631٫00
متوفر
20mg
6361٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

COX/5-LO-IN-1 is an inhibitor of cylooxygenase and 5-lipoxygenase, used for the research of inflammatory and allergic disease states.

COX/5-LO-IN-1 reduces the biosynthesis of leukotrienes B4, C4, D4, and E4 and cyclooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states[1]. COX/5-LO-IN-1 shows inhibitory activities against 5-lipoxygenase, with IC50 of 0.2 μM in human whole blood[2].

[1]. Lipoxygenase and cyclooxygenase inhibiting compounds. US 5516789 A [2]. Brooks CD, et al. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. J Med Chem. 1995 Nov 24;38(24):4768-75.

مراجعات

Review for COX/5-LO-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for COX/5-LO-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.